PierianDx and Syapse Partner to Accelerate Precision Medicine Programs for Healthcare Providers
by Josh Forsythe, on October 29, 2015
ST. LOUIS, MO and PALO ALTO, CA – PierianDx, makers of the leading bioinformatics platform for clinical genomics testing, and Syapse, the leading provider of precision medicine software, announced a partnership that will accelerate the adoption of precision medicine by healthcare systems. The companies will provide functional integration between PierianDx’s Clinical Genomicist WorkstationTM and Syapse Precision Medicine PlatformSM in order to streamline the end-to-end genomic testing workflow for hospitals with in-house labs.
Using Syapse, healthcare systems will be able to integrate molecular test results generated in PierianDx’s Clinical Genomicist Workstation with clinical data from the electronic health record, providing physicians with molecularly informed decision support at the point of care. The PierianDx NGS Gateway Program, which provides an outsourced lab testing service, will integrate directly with Syapse, streamlining test ordering and results delivery to customers.
“As genomic testing becomes a routine part of cancer care, healthcare provider systems are increasingly implementing molecular profiling testing services within their internal pathology laboratories,” said Jonathan Hirsch, Founder & President of Syapse. “Our partnership with PierianDx will supply healthcare systems’ in-house labs with a simpler and more integrated workflow. The PierianDx bioinformatics platform and testing services will ultimately speed the delivery of precision care to patients.”
In addition, the partnership will give customers the option to utilize the PierianDx Collaborative Knowledgebase™ from within Syapse, providing clinicians with meaningful medical insights for patient-specific disease conditions. The knowledgebase includes up-to-the-moment curated publications, biological information, computational predictions, population frequency data, clinical research and trial correlations, and disease variants reported in clinical databases.
“This partnership offers the best of both worlds to our clients,” said Ted Briscoe, CEO of PierianDx. “Integrating Syapse’s industry-leading precision medicine platform with PierianDx’s laboratory workflow and Collaborative Knowledgebase provides a powerful solution to advance patient care and treatment.”
PierianDx enables clinical labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. In use since 2011, and regularly enhanced with new patient, clinical and research data, PierianDx’s proprietary Clinical Genomicist Workstation software provides clinical labs everything they need to manage their next-generation sequencing processes. For more information, please visit pieriandx.com or @PierianDx on Twitter.
Syapse software enables healthcare providers to deploy precision medicine programs. Leading academic and community healthcare providers use the Syapse Precision Medicine Data Platform to integrate complex genomic and clinical data to provide clinicians with actionable insights at point of care, enabling diagnosis, treatment, and outcomes tracking. Headquartered in Palo Alto, California, Syapse is backed by The Social+Capital Partnership and Safeguard Scientifics (NYSE:SFE). For more information, visit www.syapse.com.